Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Effect of Androgen Deprivation Therapy on Other-Cause of Mortality in Elderly Patients with Clinically Localized Prostate Cancer Treated with Modern Radiotherapy: Is There a Negative Impact?

Yamazaki H, Masui K, Suzuki G, Nakamura S, Aibe N, Shimizu D, Yamada K, Okihara K, Shiraishi T, Kotsuma T, Yoshida K, Tanaka E, Otani K, Yoshioka Y, Ogawa K, Nishikawa T, Okabe H.

J Clin Med. 2019 Mar 11;8(3). pii: E338. doi: 10.3390/jcm8030338.

2.

Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer.

Wilcox SW, Aherne NJ, Benjamin LC, Wu B, de Campos Silva T, McLachlan CS, McKay MJ, Last AJ, Shakespeare TP.

Onco Targets Ther. 2014 Aug 30;7:1519-23. doi: 10.2147/OTT.S65238. eCollection 2014.

3.

Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.

Abdollah F, Sammon JD, Reznor G, Sood A, Schmid M, Klett DE, Sun M, Aizer AA, Choueiri TK, Hu JC, Kim SP, Kibel AS, Nguyen PL, Menon M, Trinh QD.

Eur J Surg Oncol. 2015 Nov;41(11):1529-39. doi: 10.1016/j.ejso.2015.06.011. Epub 2015 Jul 15.

PMID:
26210655
4.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
5.

Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.

Kovtun KA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

Cancer. 2016 Dec 1;122(23):3608-3614. doi: 10.1002/cncr.30224. Epub 2016 Aug 4.

6.

Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.

Koo KC, Cho JS, Bang WJ, Lee SH, Cho SY, Kim SI, Kim SJ, Rha KH, Hong SJ, Chung BH.

Cancer Res Treat. 2018 Jan;50(1):129-137. doi: 10.4143/crt.2017.004. Epub 2017 Mar 8.

7.

The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.

Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM.

Can J Urol. 2017 Feb;24(1):8656-8662.

PMID:
28263132
8.

Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.

Falchook AD, Basak R, Mohiuddin JJ, Chen RC.

Cancer. 2016 Aug 1;122(15):2341-9. doi: 10.1002/cncr.30049. Epub 2016 May 18.

9.

American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.

Keyes M, Merrick G, Frank SJ, Grimm P, Zelefsky MJ.

Brachytherapy. 2017 Mar - Apr;16(2):245-265. doi: 10.1016/j.brachy.2016.11.017. Epub 2017 Jan 16. Review.

10.

Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.

Ishiyama H, Kamitani N, Kawamura H, Kato S, Aoki M, Kariya S, Matsumura T, Kaidu M, Yoshida K, Hashimoto Y, Noda Y, Lim KHC, Kawase T, Takahashi T, Inaba K, Kumano M, Yoshikawa N, Yoshioka Y, Nakamura K, Hiratsuka J, Itami J, Hayakawa K.

Brachytherapy. 2017 May - Jun;16(3):503-510. doi: 10.1016/j.brachy.2017.01.006. Epub 2017 Feb 17.

PMID:
28222973
11.

High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.

Edelman S, Liauw SL, Rossi PJ, Cooper S, Jani AB.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1473-9. doi: 10.1016/j.ijrobp.2011.10.036. Epub 2012 Jan 13.

PMID:
22245201
12.

Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.

Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Inokuchi H, Nakamura K, Kamba T, Inoue T, Kamoto T, Ogawa O, Hiraoka M.

Int J Clin Oncol. 2016 Feb;21(1):148-55. doi: 10.1007/s10147-015-0867-7. Epub 2015 Jul 4.

PMID:
26141133
13.

Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?

Tabata R, Kimura T, Kuruma H, Sasaki H, Kido M, Miki K, Takahashi H, Aoki M, Egawa S.

Cancer Med. 2016 Sep;5(9):2314-22. doi: 10.1002/cam4.820. Epub 2016 Jul 25.

14.

Favorable 10-year outcomes of image-guided intensity-modulated radiotherapy combined with long-term androgen deprivation for Japanese patients with nonmetastatic prostate cancer.

Tomita N, Soga N, Ogura Y, Furusawa J, Tanaka H, Koide Y, Tachibana H, Kodira T.

Asia Pac J Clin Oncol. 2019 Feb;15(1):18-25. doi: 10.1111/ajco.13097. Epub 2018 Nov 8.

PMID:
30411504
15.

Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series.

Wilcox SW, Aherne NJ, McLachlan CS, McKay MJ, Last AJ, Shakespeare TP.

J Med Imaging Radiat Oncol. 2015 Feb;59(1):125-33. doi: 10.1111/1754-9485.12275. Epub 2015 Jan 15.

PMID:
25588566
16.

High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.

Pickles T, Morris WJ, Keyes M.

Brachytherapy. 2017 Nov - Dec;16(6):1101-1105. doi: 10.1016/j.brachy.2017.08.003. Epub 2017 Oct 12.

PMID:
29032014
17.

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):32-43.

PMID:
15629591
18.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
19.

Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.

Vargas CE, Alam NB, Terk M, Niska JR, Cesaretti J, Swartz D, Vashi A, Kasraeian A, West CS, Blasser M, Moore C.

Cancer Treat Res Commun. 2019;19:100119. doi: 10.1016/j.ctarc.2019.100119. Epub 2019 Feb 10.

PMID:
30772671
20.

Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.

Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD.

Urol Oncol. 2016 Apr;34(4):165.e1-9. doi: 10.1016/j.urolonc.2015.11.004. Epub 2015 Dec 11.

PMID:
26699831

Supplemental Content

Support Center